Yondelis Iniciara en Breve un Ensayo de Fase II . An Analysis of the Changes in the Sarcoma Tumor Immune Microenvironment Following Trabectedin .

View of NCT03397186 on 2018_02_11

ClinicalTrials Identifier:	NCT03397186
Updated:	2018 - 02 -11

Brief title : Immune Changes Following Trabectedin in Patients With Metastatic or Unresectable Sarcoma .

Official title : An Analysis of the Changes in the Sarcoma Tumor Immune Microenvironment Following Trabectedin .

Sponsors and Collaborators :

*.- Fred Hutchinson Cancer Research Center
*.- National Cancer Institute (NCI)
*.- Janssen Pharmaceuticals

Status : Not yet recruiting
Start date : 2018-05-01 (Anticipated)
Last follow-up date : 2019-05-01 (Anticipated)
Primary completion date : 2019-05-01 (Anticipated)

Studies a U.S. FDA-Regulated Drug Product : Yes